Seastar Medical Holding CORP 10-Q quarterly reports

SeaStar Medical Holding Corporation reported increased revenue in Q1 2026 driven by QUELIMMUNE adoption, though net losses persisted.

SeaStar Medical Holding Corporation reported reduced net losses and increased cash, but faces substantial doubt about its ability to continue as a going concern and a Nasdaq minimum bid price non-compliance.

SeaStar Medical Holding Corporation reported a significant reduction in net loss and increased cash reserves for the first half of 2025, driven by initial commercial sales of QUELIMMUNE and reduced operating expenses, despite ongoing liquidity concerns.

SeaStar Medical Holding Corporation reports its Q1 2025 financial results, highlighting initial revenue from its pediatric Selective Cytopheretic Device (SCD) therapy and ongoing clinical trials for adult applications.

SeaStar Medical's Q3 2024 report reveals initial revenue from pediatric device sales, alongside ongoing financial losses and a need for additional capital.

SeaStar Medical's Q2 2024 results show a net loss of $3.2 million, with the company facing liquidity concerns despite FDA approval and initial commercial shipments of its pediatric SCD device.

SeaStar Medical's Q1 2024 results show a net loss of $12.7 million and raise concerns about the company's ability to continue as a going concern.